Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease

다국어 초록 (Multilingual Abstract)

The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia (ALL).
This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome–negative ALL who were receiving frontline chemotherapy. Three hundred thirty patients (77%) were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone–based regimens, and 98 (23%) were treated with the augmented Berlin‐Frankfurt‐Munster regimen.
The median age was 40 years (range, 13‐86 years). One hundred eighty‐six patients (43%) had diploid cytogenetics, 32 (7%) had complex cytogenetics (defined as ≥ 5 chromosomal abnormalities), 27 (6%) had low hypodiploidy/near‐triploidy (Ho‐Tr), 24 (6%) had high hyperdiploidy, and 24 (6%) had a mixed‐lineage leukemia (MLL) rearrangement. Patients with an MLL rearrangement, Ho‐Tr, or a complex karyotype had significantly worse relapse‐free survival (RFS) and overall survival (OS) than the diploid group. According to a multivariate analysis including all the baseline characteristics and MRD status, Ho‐Tr and a complex karyotype were independent predictive factors for worse RFS and OS. Furthermore, survival among all cytogenetic groups was similar, regardless of the treatment received.
A complex karyotype and Ho‐Tr are adverse prognostic factors for adults with ALL independently of the MRD status. These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population. Cancer 2017;123:459–467. © 2016 American Cancer Society.
In adult patients with acute lymphoblastic leukemia, low hypodiploidy/near‐triploidy and a complex karyotype are associated with worse survival independently of minimal residual disease response. Pretreatment cytogenetics should still be used for the risk stratification of patients with acute lymphoblastic leukemia.